Navigation Links
InVitria Touts Product Advantages at Cambridge's Cell Culture Conference

FORT COLLINS, Colo., Sept. 24 /PRNewswire/ -- InVitria ( addressed attendees at Cambridge Healthtech Institute's 4th Annual "Optimizing Cell Culture Development" Conference on September 15-16 in Boston, Massachusetts and announced its most recent results optimizing cell culture media using its product line of animal free cell culture ingredients. (

In a presentation of scientific studies with InVitria's Cellastim and Lacromin, Steve Pettit, Director of InVitria's Cell Culture Group, noted, "The growth and productivity results in CHO cell lines are quite impressive and not achievable with other sources of albumin or transferrin supplements. Cellastim has shown growth and productivity up to 50% better than the next best alternative. Similar impressive results with the use of Lacromin have previously been published by our team(1)," said Pettit.

"We continue to show powerful results of Cellastim and Lacromin in cell culture media for a variety of cell lines including CHO, Hybridoma, Vero and NS0 cells. Since these are well defined supplements, they help our customers achieve both their regulatory and manufacturing goals. These are the only supplements available that not only improve cell culture performance, but do this while maintaining a defined and animal free media," said Scott Deeter, InVitria's President.

About InVitria (

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim - Cellastim is a recombinant albumin that is used as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity. Cellastim also has been an effective component in stem cell media and primary cell media.(see

-- Lacromin - Lacromin is recombinant human lactoferrin, a growth factor that also delivers iron similar to transferrin in cell culture media. (see

-- Lysobac - Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher recombinant protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields.(see

(1) Huang et al. Bioactive Recombinant Human Lactoferrin Stimulates Mammalian Cell Growth. Society for InVitro Biology. InVitro Cell Develop. Biology. May 6, 2008.

For more information about the InVitria line of products, please e-mail or call 1-800-916-8311.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitria Sponsors Cambridge Healthtechs Optimizing Cell Culture Development Conference
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. InVitria Expands Sales Team
4. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
5. Gores Legacy of Innovation Extends From Products to Processes
6. Martek is Now the Sole-Source Supplier of ARA for all Infant Formula Products Manufactured by Hochdorf Nutricare
7. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
8. Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment
9. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
10. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
11. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):